Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia

The New England Journal of Medicine
H G Welch, E B Larson

Abstract

To compare the cost effectiveness of bone marrow transplantation and conventional chemotherapy, we evaluated the resources used in the care of adult patients with acute nonlymphocytic leukemia who were enrolled in a prospective trial and received induction chemotherapy at a single university hospital. Nineteen patients were subsequently treated with chemotherapy and 17 with transplantation. Cost accounting began with induction chemotherapy and extended over a five-year period. Costs were estimated by means of a resource-based, multivariate prediction model. The transplantation and chemotherapy groups had virtually equivalent use of resources (hospital days, laboratory tests, blood products, and radiologic and operative procedures) over five years, except for a 10-fold increase in the use of the intensive care unit for the patients who underwent transplantation (P less than 0.001). The total costs over five years were estimated at $193,000 per patient for transplantation and $136,000 per patient for chemotherapy (P = 0.02). At five years, the costs per year of life saved ("life-year") were nearly equal ($62,500 per life-year for transplantation vs. $64,000 per life-year for chemotherapy) because of the better rate of disease-fre...Continue Reading

References

Oct 25, 1979·The New England Journal of Medicine·J P KoplanD W Fraser
Mar 31, 1977·The New England Journal of Medicine·M C Weinstein, W B Stason
Feb 1, 1976·Cancer·R J EsterhayP H Wiernik
Jan 1, 1985·Annual Review of Public Health·M C Weinstein, W B Stason
Jun 1, 1986·The Surgical Clinics of North America·R W Evans
Sep 12, 1986·JAMA : the Journal of the American Medical Association·G OsterG A Colditz
Mar 1, 1987·Journal of Health and Social Behavior·N G Kutner
Apr 22, 1988·JAMA : the Journal of the American Medical Association·J S Mandelblatt, M C Fahs
Aug 20, 1987·The New England Journal of Medicine·S WoolhandlerS Lang
Apr 11, 1986·JAMA : the Journal of the American Medical Association·R W EvansA M Maier
Jun 1, 1986·Annals of Surgery·H T BahnsonS Iwatsuki
Sep 1, 1986·Transplantation·M M Bortin, A A Rimm
Jan 1, 1985·American Journal of Public Health·G J Annas
Sep 26, 1985·The New England Journal of Medicine·P G BeattyR Storb
Mar 1, 1973·The Journal of Surgical Research·J M Civetta
Jan 1, 1982·Annals of Internal Medicine·S A Finkler

❮ Previous
Next ❯

Citations

Jan 1, 1993·Stem Cells·S GulatiC Van-Poznak
Apr 1, 1993·Journal of Religion and Health·Joseph J Fins, Curtis W Hart
Oct 23, 2010·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Osamu ImatakiYoichi Takaue
Feb 1, 1995·Social Science & Medicine·N E BushK M Sullivan
Oct 1, 1994·Social Science & Medicine·R K Lie
Apr 3, 2004·Cancer Treatment Reviews·Alberto RedaelliChris L Pashos
Jan 15, 1997·International Journal of Radiation Oncology, Biology, Physics·A A KonskiS R Zeidner
Aug 1, 1997·Seminars in Oncology Nursing·P M Kapustay
Aug 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A MessoriE Tendi
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B E Hillner
Feb 19, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K BergerT D Szucs
Feb 22, 2002·Critical Reviews in Oncology/hematology·Gian Luigi Cetto, Annamaria Molino
Jan 1, 1994·International Journal of Technology Assessment in Health Care·G R TennvallB Nilsson
Sep 13, 1990·The New England Journal of Medicine·K M SullivanR P Witherspoon
Sep 1, 1994·The New England Journal of Medicine·N F OlivieriA R Cohen
Aug 1, 1997·The American Journal of the Medical Sciences·F M WeeksJ R Wingard
Dec 6, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·T D SzucsK J Dedes
Jun 30, 1998·APMIS. Supplementum·J Olweus
Nov 20, 1993·BMJ : British Medical Journal·E Z OddoneJ R Feussner
Jan 1, 2010·ClinicoEconomics and Outcomes Research : CEOR·Thomas Bart
Oct 22, 2013·Haematologica·Myriam LabopinUNKNOWN Eurocord and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
Nov 1, 1995·Intensive Care Medicine·D B ChalfinJ Lambrinos
Nov 17, 2015·Expert Review of Hematology·Amer M ZeidanB Douglas Smith
Jan 1, 1994·Cancer Investigation·C L BennettS Gulati
Jan 1, 1997·Cancer Investigation·C L Bennett, T M Waters
Jan 1, 1991·Journal of Clinical Epidemiology·S J Skates, D E Singer
Mar 1, 1992·The American Journal of Medicine·D M MastrianniD G Tenen
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M Goddard, M Drummond
Feb 1, 1993·Critical Reviews in Oncology/hematology·A J Murgo, B B Weinberger
Jun 1, 1991·Blood Reviews·J R ChapmanH Lapsley
Jun 16, 2012·Blood·Nandita KheraStephanie J Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.